MedWorm: Avastin

SIR: Combo of Embolization and Bevacizumab Safe (CME/CE)

MedPage Today Radiology — Fri, 19 Mar 2010 15:48:38 +0100

TAMPA (MedPage Today) -- Giving bevacizumab (Avastin) concurrently with transarterial chemoembolization (TACE) is reasonably well tolerated and appears to be effective in patients with inoperable hepatocellular carcinoma, researchers said here. (Source: MedPage Today Radiology)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Intravitreal bevacizumab vs intravitreal triamcinolone combined with macular laser grid for diffuse diabetic macular oedema

Eye — Fri, 19 Mar 2010 00:00:00 +0100

Authors: R Forte, G L Cennamo, M Finelli, E Farese, G D'Amico, G Nicoletti, G de Crecchio & G Cennamo (Source: Eye)

Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer [Thoracic Oncology]

Journal of Clinical Oncology — Thu, 18 Mar 2010 22:01:36 +0100

Conclusion Dulanermin plus PCB was well tolerated with no occurrence of DLTs and demonstrated antitumor activity in this patient population. Dulanermin at 8 mg/kg/d for 5 days and 20 mg/kg/d for 2 days every 3 weeks in combination with PCB is being studied in a phase II trial. (Source: Journal of Clinical Oncology)

Study hails "sight-saving" drug

Nursing in Practice — Wed, 17 Mar 2010 14:56:55 +0100

Two patients threatened with blindness by a rare condition have had their sight saved by the drug Avastin, a consultant has claimed (Source: Nursing in Practice)

Drug helps fight rare eye condition

Pharmacy Europe — Wed, 17 Mar 2010 14:15:38 +0100

An eye unit has revealed how Avastin helped save the sight of two people suffering with the rare condition, Sorsby's Fundus Dystrophy (SFD) (Source: Pharmacy Europe)

Effectiveness and Safety of Bevacizumab for Unresectable Non-Small-Cell Lung Cancer: A Meta-Analysis

Clinical Drug Investigation — Wed, 17 Mar 2010 14:14:51 +0100

(Source: Clinical Drug Investigation)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Unique use of drug saves eyesight

Nursing Times Breaking News — Wed, 17 Mar 2010 10:20:00 +0100

The drug Avastin has been used to save the eyesight of two patients with Sorsby’s Fundus Dystrophy (SFD), a rare form of macular degeneration, an ophthalmologist has revealed. (Source: Nursing Times Breaking News)

Incidence and Management of Acute Endophthalmitis After Intravitreal Bevacizumab (Avastin) Injection

Medscape Ophthalmology Headlines — Tue, 16 Mar 2010 16:54:48 +0100

What's the risk of acute endophthalmitis after intravitreal bevacizumab injection and what can be done to lower the risk? Eye (Source: Medscape Ophthalmology Headlines)

Costs Of Adverse Events In First-Line Metastatic Renal Cell Carcinoma Treatment: Bevacizumab In Combination With Interferon-a2a Vs Sunitinib

Health News from Medical News Today — Tue, 16 Mar 2010 12:00:00 +0100

UroToday.com - The availability of novel and promising targeted therapies for the treatment of patients with metastatic renal cell carcinoma (RCC), such as bevacizumab plus interferon and sunitinib, has meant important increases in options for patients and physicians treating this deadly disease. It has also meant that patients can take medications, non-curatively, for long periods of time. So an understanding of the treatment-associated side effects with these therapies is very important, as is an understanding of the costs of these treatments... (Source: Health News from Medical News Today)

Costs Of Adverse Events In First-Line Metastatic Renal Cell Carcinoma Treatment: Bevacizumab In Combination With Interferon-a2a Vs Sunitinib

Urology / Nephrology News From Medical News Today — Tue, 16 Mar 2010 12:00:00 +0100

UroToday.com - The availability of novel and promising targeted therapies for the treatment of patients with metastatic renal cell carcinoma (RCC), such as bevacizumab plus interferon and sunitinib, has meant important increases in options for patients and physicians treating this deadly disease. It has also meant that patients can take medications, non-curatively, for long periods of time... (Source: Urology / Nephrology News From Medical News Today)

Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study

Acta Ophthalmologica — Tue, 16 Mar 2010 00:00:00 +0100

Conclusion: The results of our 12-month prospective study indicate that intravitreal bevacizumab alone has similar efficacy and safety to bevacizumab plus PDT for treatment of patients with neovascular AMD, even treatment-naïve patients. The addition of PDT did not assist in reducing the required total number of bevacizumab injections. (Source: Acta Ophthalmologica)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Phage display peptide probes for imaging early response to bevacizumab treatment.

Amino Acids — Tue, 16 Mar 2010 00:00:00 +0100

Authors: Cao Q, Liu S, Niu G, Chen K, Yan Y, Liu Z, Chen X Early evaluation of cancer response to a therapeutic regimen can help increase the effectiveness of treatment schemes and, by enabling early termination of ineffective treatments, minimize toxicity, and reduce expenses. Biomarkers that provide early indication of tumor therapy response are urgently needed. Solid tumors require blood vessels for growth, and new anti-angiogenic agents can act by preventing the development of a suitable blood supply to sustain tumor growth. The purpose of this study is to develop a class of novel molecular imaging probes that will predict tumor early response to an anti-angiogenic regimen with the humanized vascular endothelial growth factor antibody bevacizumab. Using a bevacizumab-sensitive LS17...

Contrast sensitivity after intravitreal antivascular endothelial growth factor therapy for myopic choroidal neovascularization

Graefe's Archive for Clinical and Experimental Ophthalmology — Mon, 15 Mar 2010 17:54:58 +0100

Conclusions Improvements in Pelli-Robson CS scores were observed during the first year after IVR/IVB in eyes with mCNV. Content Type Journal ArticleCategory Retinal DisordersDOI 10.1007/s00417-010-1341-xAuthors Sarah Moussa, The Ludwig Boltzmann Institute for Retinology and Biomicroscopic Laser Surgery Vienna AustriaSiamak Ansari-Shahrezaei, The Ludwig Boltzmann Institute for Retinology and Biomicroscopic Laser Surgery Vienna AustriaEva Smretschnig, The Ludwig Boltzmann Institute for Retinology and Biomicroscopic Laser Surgery Vienna AustriaStefan Hagen, The Ludwig Boltzmann Institute for Retinology and Biomicroscopic Laser Surgery Vienna AustriaKerstin Steindl-Kuscher, The Ludwig Boltzmann Institute for Retinology and Biomicroscopic Laser Surgery Vienna AustriaIlse Kre...

Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma

The Journal of Experimental Medicine — Mon, 15 Mar 2010 17:12:56 +0100

This study may be useful in paving the way toward a more rational development of second generation antiangiogenic combination therapies and in providing, for the first time, a murine model to study this. (Source: The Journal of Experimental Medicine)

Bevacizumab in combination with sequential high-dose chemotherapy in solid cancer, a feasibility study

Bone Marrow Transplantation — Mon, 15 Mar 2010 00:00:00 +0100

Authors: K Jordan, H H Wolf, W Voigt, T Kegel, L P Mueller, T Behlendorf, C Sippel, D Arnold & H J Schmoll (Source: Bone Marrow Transplantation)

Aneurysm formation in an angiomyolipoma during bevacizumab combination therapy.

Acta Oncologica — Mon, 15 Mar 2010 00:00:00 +0100

Authors: Maleux G, Vaninbroukx J, Heye S, Cutsem EV, Oyen R PMID: 20230212 [PubMed - as supplied by publisher] (Source: Acta Oncologica)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer

Angiogenesis — Sun, 14 Mar 2010 12:26:49 +0100

Abstract Tumor neovascularization is a complex process that plays a crucial role in the development of many different types of cancer. Vascular endothelial growth factor (VEGF) is a potent mitogen that is involved with mitogenesis, angiogenesis, endothelial survival, and the induction of hematopoiesis. By increasing vascular permeability in endothelial cells, it helps tumors recruit wound-healing proteins fibrin and fibrinogen from the plasma, suggesting that tumor formation is a process of abnormal wound healing dependent on the ability to generate a blood supply. The human female reproductive tract is highly dependent on VEGF for normal functions such as endometrial proliferation and development of the corpus luteum. The unique influence of female sex steroid hormones on...

Genentech Provides Update On Phase III Study Of Avastin In Men With Late Stage Prostate Cancer

Health News from Medical News Today — Sun, 14 Mar 2010 07:00:00 +0100

Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the topline results of a Phase III trial led by the U.S. Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute (NCI) investigating the use of Avastin® (bevacizumab) in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer (hormone-refractory / HRPC). The study, known as CALGB 90401, did not meet its primary objective of extending overall survival compared to chemotherapy and prednisone alone... (Source: Health News from Medical News Today)

Genentech Provides Update On Phase III Study Of Avastin In Men With Late Stage Prostate Cancer

Cancer / Oncology News From Medical News Today — Sun, 14 Mar 2010 07:00:00 +0100

Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the topline results of a Phase III trial led by the U.S... (Source: Cancer / Oncology News From Medical News Today)

Avastin fails in prostate cancer trial

bizjournals.com Health Care:Biotechnology headlines — Fri, 12 Mar 2010 17:46:33 +0100

Cancer drug Avastin failed to extend the life of men with late-stage prostate cancer, Genentech Inc. and parent company Roche said late Thursday. (Source: bizjournals.com Health Care:Biotechnology headlines)

Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.

World Journal of Gastroenterology : WJG — Fri, 12 Mar 2010 17:05:31 +0100

Authors: Saridaki Z, Georgoulias V, Souglakos J Metastatic colorectal cancer (mCRC) continues to be counted as a major health problem. The introduction of newer cytotoxics, irinotecan and oxaliplatin, has achieved a significant improvement in survival rates. Novel targeted therapies (bevacizumab, and cetuximab) in combination with most efficient chemotherapy regimens have pushed the median survival beyond the 2-year mark and increased the proportion of patients which could benefit from resection of metastatic lesions. In addition, several studies have proved that the CRC mutation profiles should influence patient selection or stratification in prospective trials. KRAS mutational status represents a paradigm for biomarker development in the era of molecular targeted therapies. The prese...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Avastin Fails Clinical Trial for Prostate Cancer

NYT > Health — Fri, 12 Mar 2010 15:38:19 +0100

The miss in prostate cancer follows a similar disappointment with Avastin in gastric cancer but success in ovarian cancer. (Source: NYT > Health)

Genentech Provides Update on Phase III Study of Avastin in Men With Late Stage Prostate Cancer

HSMN NewsFeed — Fri, 12 Mar 2010 12:44:05 +0100

SOUTH SAN FRANCISCO, Calif.--(HSMN NewsFeed)--Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the topline results of a Phase III trial led by the U.S. Cancer and Leukemia Group B (CALGB) and sponsored... Biopharmaceuticals, OncologyGenentech, Roche Group, Avastin, bevacizumab, prostate cancer, CALGB 90401 (Source: HSMN NewsFeed)

Genentech Says Avastin Trial Did Not Meet Goal

Drugs.com - Pharma News — Fri, 12 Mar 2010 12:40:09 +0100

From Associated Press (March 12, 2010) NEW YORK -- Roche’s efforts to win new marketing approvals for a cancer treatment candidate hit another stumbling block Friday as the Swiss drugmaker said Avastin did not improve survival among prostate... (Source: Drugs.com - Pharma News)

Genentech Provides Update on Phase III Study of Avastin in Men With Late Stage Prostate Cancer

Drugs.com - Clinical Trials — Fri, 12 Mar 2010 12:17:17 +0100

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 12, 2010 - Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the topline results of a Phase III trial led by the U.S. Cancer and Leukemia Group B... (Source: Drugs.com - Clinical Trials)

Roche provides update on phase III study of Avastin in men with late stage prostate cancer

Roche Media News — Fri, 12 Mar 2010 06:00:00 +0100

Roche announced today the topline results of a phase III trial led by the US Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute investigating the use of Avastin (bevacizumab) in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer (hormone-refractory / HRPC). The study, known as CALGB 90401, did not meet its primary objective of extending overall survival compared to chemotherapy and prednisone alone. A preliminary assessment of safety performed by CALGB has shown adverse events that have been previously observed in pivotal trials with Avastin. (Source: Roche Media News)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Roche provides update on phase III study of Avastin in men with late stage prostate cancer

Roche Investor Update — Fri, 12 Mar 2010 06:00:00 +0100

Photodynamic therapy alone versus combined with intravitreal bevacizumab for neovascular age-related macular degeneration without polypoidal choroidal vasculopathy in Japanese patients

Graefe's Archive for Clinical and Experimental Ophthalmology — Thu, 11 Mar 2010 02:40:18 +0100

Conclusions Our 12-month results of PDT combined with IVB for Japanese patients with AMD without PCV appeared to be more effective than those of PDT alone with fewer treatments. Content Type Journal ArticleCategory Retinal DisordersDOI 10.1007/s00417-010-1343-8Authors Ryuhei Hara, Kumamoto University Department of Ophthalmology and Visual Science, Graduate School of Medical Sciences 1-1-1 Honjo Kumamoto 860-8556 JapanTakahiro Kawaji, Kumamoto University Department of Ophthalmology and Visual Science, Graduate School of Medical Sciences 1-1-1 Honjo Kumamoto 860-8556 JapanYasuya Inomata, Kumamoto University Department of Ophthalmology and Visual Science, Graduate School of Medical Sciences 1-1-1 Honjo Kumamoto 860-8556 JapanJin Tahara, Kumamoto University Department of...

Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome

Graefe's Archive for Clinical and Experimental Ophthalmology — Thu, 11 Mar 2010 02:40:15 +0100

Conclusions Intravitreal bevacizumab seems to be effective for subfoveal and juxtafoveal CNV in highly myopic eyes. BCVA gain decreases and is no longer significant by the end of the second year. Content Type Journal ArticleCategory Retinal DisordersDOI 10.1007/s00417-010-1340-yAuthors Jose M. Ruiz-Moreno, Castilla La Mancha University Department of Ophthalmology Albacete SpainJavier A. Montero, Alicante Institute of Ophthalmology, VISSUM, Vitreo-Retinal Unit Alicante Spain Journal Graefe's Archive for Clinical and Experimental OphthalmologyOnline ISSN 1435-702XPrint ISSN 0721-832X (Source: Graefe's Archive for Clinical and Experimental Ophthalmology)

Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer

Cancer — Thu, 11 Mar 2010 00:00:00 +0100

Bevacizumab has recently been demonstrated to prolong overall survival when added to carboplatin and paclitaxel for chemotherapy-naïve patients with nonsquamous nonsmall-cell lung cancer (NSCLC). However, the effects of combining bevacizumab with other standard, front-line, platinum-based doublets have not been extensively explored. We designed this single treatment arm, phase 2 trial to determine whether the combination of carboplatin, docetaxel, and bevacizumab is tolerable and prolongs progression-free survival of chemotherapy-naïve patients with advanced, nonsquamous NSCLC.Forty patients were treated with up to 6 cycles of carboplatin (AUC 6), docetaxel (75 mg/m2), and bevacizumab (15 mg/kg) on Day 1 every 21 days. Patients with an objective response or stable disease received mainte...

Review: New strategies in the management of leptomeningeal metastases

NeLM - News — Thu, 11 Mar 2010 00:00:00 +0100

Source: Archives of Neurology Area: News The Archives of Neurology have featured a review on the management of patients with leptomeningeal metastases (LM). The review discusses the following: . The biology of central nervous system metastases and LM . Drug delivery . Treatments, including intrathecal treatments, systemic treatments (methotrexate, capecitabine, temozolomide), hormonal therapies, and experimental treatments (pemetrexed, bevacizumab, gefitinib) . Early treatment/prevention opportunities (Source: NeLM - News)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Nasal septum perforation and bevacizumab

Medical Oncology — Wed, 10 Mar 2010 16:02:59 +0100

Abstract The use of targeted/biologic therapies is now commonplace in the treatment of malignant and non-malignant diseases. The novel mode of action of these drugs has resulted in unpredictable and in some cases unexpected side effects. Given the widespread use of bevacizumab and its distinct mode of action, it is important that oncologists report any unexpected adverse events that may be associated with the drug. Herein, we report three cases of spontaneous nasal septum perforation secondary to bevacizumab. We hypothesize an etiology for this rare event and reasons why it is reasonable to rechallenge the patient. Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12032-010-9464-9Authors Derek G. Power, Memorial Sloan Kettering Cancer Center Department o...

Avastin fight now moves to P.E.I.

CBC | Health — Wed, 10 Mar 2010 02:49:26 +0100

A cancer patient who successfully helped lobby the New Brunswick government to fund an expensive cancer drug is now shifting his focus to P.E.I. in an effort to have Avastin funded by that province. (Source: CBC | Health)

Review: Bevacizumab for malignant gliomas

NeLM - News — Wed, 10 Mar 2010 00:00:00 +0100

Source: Arch Neurol Area: News The Archives of Neurology has featured a review on bevacizumab for malignant gliomas. The review discusses the following: . Rationale for antiangiogenic therapies in malignant gliomas . Bevacizumab in malignant gliomas . Potential limitations of antiangiogenic therapy in glioma (Source: NeLM - News)

Anti-AMD Drug Use Stirs Concern in Canada (CME/CE)

MedPage Today Public Health — Tue, 09 Mar 2010 14:29:32 +0100

Intravitreal drug injections for age-related macular degeneration in at least one Canadian province have mushroomed in recent years, likely adding fuel to a controversy over off-label use of bevacizumab for this purpose. (Source: MedPage Today Public Health)

Macular ischaemia after intravitreal bevacizumab injection in patients with central retinal vein occlusion and a history of diabetes and vascular disease

British Journal of Ophthalmology — Tue, 09 Mar 2010 12:49:03 +0100

(Source: British Journal of Ophthalmology)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Everolimus (RAD001) in the Treatment of Advanced Renal Cell Carcinoma: A Review.

The Oncologist — Tue, 09 Mar 2010 00:00:00 +0100

Authors: Agarwala SS, Case S Abstract Historically, there have been few treatment options for patients with advanced renal cell carcinoma (RCC) besides immunotherapy with interleukin-2 and interferon (IFN)-alpha. Targeted therapies have improved clinical outcomes over the past several years. These include the vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors sunitinib and sorafenib, which inhibit angiogenic signaling in endothelial cells and vascular pericytes predominantly through VEGFR and platelet-derived growth factor receptor beta. Also included is the anti-VEGF monoclonal antibody bevacizumab used in combination with IFN-alpha. These agents mediate their antitumor effects by interfering with the VEGF signaling pathway, thereby inhibiting angiogenesis ...

Pemetrexed Plus Bevacizumab for Second-Line Therapy of Non-Small-Cell Lung Cancer: The Importance of Patient Selection [CORRESPONDENCE]

Journal of Clinical Oncology — Mon, 08 Mar 2010 23:01:30 +0100

(Source: Journal of Clinical Oncology)

Rapid Expansion of Intravitreal Drug Injection Procedures, 2000 to 2008: A Population-Based Analysis [Socioeconomics and Health Services]

Archives of Opthalmology — Mon, 08 Mar 2010 20:50:47 +0100

Conclusions The development of vascular endothelial growth factor inhibitors has revolutionized the treatment of age-related macular degeneration. To our knowledge, this study is the first to quantify the dramatic uptake of these treatments at a population level. Our findings also suggest that off-label injection of bevacizumab was highly prevalent in Ontario. Serial intravitreal injections requiring direct physician administration and the concentration of injection procedures in the hands of a small number of ophthalmologists have the potential to affect services for other vision-threatening conditions. (Source: Archives of Opthalmology)

Bevacizumab for Malignant Gliomas [Neurological Review]

Archives of Neurology — Mon, 08 Mar 2010 20:50:43 +0100

Malignant gliomas are the most common and aggressive primary brain tumors in adults. Despite optimal treatment with surgery, radiotherapy, and temozolomide, tumor recurrences are frequent and patients with malignant gliomas continue to have poor prognoses. Malignant gliomas are often highly vascularized, and significant advances have been made in the last few decades in our understanding of the mechanisms of tumor angiogenesis. Recently, bevacizumab, an antibody against vascular endothelial growth factor, has demonstrated significant activity in recurrent glioblastomas, resulting in US Food and Drug Administration approval and raising the prospect for other antiangiogenic drugs now entering clinical trials. (Source: Archives of Neurology)

Recentin Did Not Meet Primary Endpoint in Horizon III Study in Metastatic Colorectal Cancer

Drugs.com - Clinical Trials — Mon, 08 Mar 2010 14:12:07 +0100

This study,... (Source: Drugs.com - Clinical Trials)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

RECENTIN Did Not Meet Primary Endpoint In Horizon III Study In Metastatic Colorectal Cancer

Pharmaceutical Online News — Mon, 08 Mar 2010 10:03:00 +0100

AstraZeneca recently announced the top-line results of a Phase II/III study evaluating RECENTIN (cediranib) compared with Avastin (bevacizumab) in patients with first-line metastatic colorectal cancer (mCRC). (Source: Pharmaceutical Online News)

Cancer drug may help treat chronic nosebleeds

Kidney Cancer Association — Fri, 05 Mar 2010 12:55:03 +0100

Dr. Davidson is testing a new approach to treatment of HHT. He's using the cancer drug Avastin in low doses in both injection and spray forms to stop the nosebleeds.03/05/2010 (Source: Kidney Cancer Association)

Gynecologic Oncology Group Notifies CTI That Continuation Of GOG-212 Pivotal Trial Of OPAXIO Maintenance Therapy In Ovarian Cancer Is A Priority

Health News from Medical News Today — Fri, 05 Mar 2010 12:00:00 +0100

Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced that CTI received a statement on March 1, 2010 from the Gynecologic Oncology Group (GOG) leadership that the phase III GOG-212 clinical trial of CTI's OPAXIO™ used as maintenance therapy for ovarian cancer remains a high priority and enrollment will continue. The GOG made the statement to clarify that the recent results of the GOG-218 clinical trial bevacizumab in maintenance therapy for ovarian cancer has not influenced the importance of completing the GOG-212 clinical trial... (Source: Health News from Medical News Today)

Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer

Gut — Fri, 05 Mar 2010 11:12:51 +0100

Conclusion This study provides the first evidence that high VFA independently predicts a poorer outcome in patients given first-line bevacizumab-based treatment for MCC. However, this predictive biomarker needs to be validated in a different dataset. (Source: Gut)

Body fatness and bevacizumab-based therapy in metastatic colorectal cancer

Gut — Fri, 05 Mar 2010 11:12:50 +0100

(Source: Gut)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

[Outlook: Future therapy of renal cell carcinoma]

Onkologie — Fri, 05 Mar 2010 00:48:02 +0100

Authors: Bergmann L, Miller K Targeted therapies have fundamentally altered the therapy of metastatic renal cell carcinoma (mRCC). Sunitinib today is an internationally recommended reference standard in first-line therapy; other drugs such as Temsirolimus, Everolimus, Bevacizumab (in combination with Interferon-alpha) and Sorafenib are part of the therapeutic arsenal. Practitioners thus have now more and better therapeutic options at hand, leading to a significantly improved prognosis for mRCC patients. Numerous ongoing research activities aim at the improvement of the benefits of the new compounds in the metastatic situation or application earlier in the course of the disease. Key aspects of future development in RCC are the optimization of the current therapy options by developing ne...

[First-line therapy of metastatic renal cell carcinoma - update 2009]

Onkologie — Fri, 05 Mar 2010 00:48:02 +0100

Authors: Miller K Several molecular therapies have recently become available in first-line therapy of metastatic renal cell carcinoma (mRCC), thus marginalizing cytocine-based therapy. The primary aim of treatment in this situation is to delay progression with an increase in long-term life expectancy along with enhanced quality of life. At present, three new substances are available: Sunitinib, Temsirolimus, and - in combination with Interferon-alpha - Bevacizumab. To date, sufficient data is at hand for all drugs, which has resulted in a consolidation of therapeutic strategy. Selecting the best therapy is highly relevant in everyday practice, depending, among other things, on clinical evidence, guidelines, and the respective approval status. The prognostic score according to Motzer (M...

Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site

Cancer — Fri, 05 Mar 2010 00:00:00 +0100

Despite the widespread use of oxaliplatin-based regimens for colorectal and other gastrointestinal cancers, there is surprisingly little information regarding their empiric use for the treatment of carcinoma of unknown primary site (CUP). In the current study, the combination of oxaliplatin and capecitabine in patients with recurrent and refractory CUP was examined.Patients with CUP who had received at least 1 previous chemotherapy regimen were treated with oxaliplatin (130 mg/m2 intravenously on Day 1) and capecitabine (1000 mg/m2 orally twice daily on Days 1-14). Treatment cycles were repeated every 21 days. Patients with objective response or stable disease after 2 cycles continued treatment for 6 cycles or until disease progression.Nine of 48 patients (19%) had objective responses to t...

mTOR pathway inhibition in renal cell carcinoma.

Urologic Oncology — Thu, 04 Mar 2010 00:00:00 +0100

Authors: Pinto Marín A, Redondo Sánchez A, Espinosa Arranz E, Zamora Auñón P, Castelo Fernández B, González Barón M Renal cell carcinoma therapy has changed in a very significant way in the last few years. Up to 5 new agents have been developed, improving the results previously achieved with cytokine therapy. Bevacizumab, sorafenib, sunitinib, temsirolimus, and everolimus are now part of the therapeutic arsenal for this illness. Particularly, this has been the first tumoral type in which inhibition of mammalian target of rapamycin (mTOR) has proved its efficacy in phase III trials, either as first-line therapy for poor prognosis patients (temsirolimus, CCI-779) or as second-line therapy after failure of tyrosine-kinase inhibitors (everolimus, RAD001)....

Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in Japan

International Journal of Clinical Oncology — Wed, 03 Mar 2010 08:51:54 +0100

Conclusions We clarified the out-of-pocket payment and cost-effectiveness of chemotherapy of MCRC patients in Japan. Our previous survey shows it is highly possible that many patients prefer to pay that incremental out-of-pocket payment to gain one additional QAPFS year. However, our cost-effectiveness analysis was not conducted from the perspective of society or healthcare payers. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s10147-010-0045-xAuthors Takeru Shiroiwa, The University of Tokyo Department of Drug Policy and Management, Graduate School of Pharmaceutical Sciences Yakugaku-toshokan 4F, 7-3-1 Hongo, Bunkyo-ku Tokyo 113-0033 JapanTakashi Fukuda, The University of Tokyo Department of Health Economics and Epidemiology Research, School of Pu...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Gertrude Elion - Pioneer of Cancer Drug Development

About.com Breast Cancer — Wed, 03 Mar 2010 00:00:00 +0100

Gertrude B. Elion Photo © Official Nobel Prize Photo 1988 Women's History Month New York City welcomed Gertrude Elion into the world in 1918 on a freezing January night. She was the child of European immigrants who encouraged her to get a good education. Gertrude attended public school in the Bronx, and when it came time to choose a major for high school, she thought of her beloved grandfather. He had spent lots of time with her and her brother when they were small, and she stayed with him until he passed away of stomach cancer. She decided on chemistry, saying, "I had no specific bent toward science until my grandfather died of cancer. I decided nobody should suffer that much." Elion started at Hunter College in 1933, the year her grandfather died. The stock market had crashed...

Bevacizumab: Endophthalmitis following intravitreal injection: 3 case reports

Reactions — Mon, 01 Mar 2010 14:50:10 +0100

(Source: Reactions)

Persistent Ocular Hypertension Following Intravitreal Bevacizumab and Ranibizumab Injections

Journal of Ocular Pharmacology and Therapeutics — Mon, 01 Mar 2010 04:56:55 +0100

Journal of Ocular Pharmacology and Therapeutics Feb 2010, Vol. 26, No. 1: 105-110. (Source: Journal of Ocular Pharmacology and Therapeutics)

Endoscopic placement of self-expandable metal stents for malignant colonic obstruction: long-term outcomes and complication factors

Gastrointestinal Endoscopy — Mon, 01 Mar 2010 00:00:00 +0100

Conclusion: Colorectal SEMS placement is relatively safe and effective but with a complication rate of nearly 25%. Patient characteristics and technical variables appear to affect the outcome of SEMS therapy. (Source: Gastrointestinal Endoscopy)

New molecular targeted therapies integrated with radiation therapy in lung cancer.

Clinical Lung Cancer — Mon, 01 Mar 2010 00:00:00 +0100

Authors: Provencio M, Sánchez A, Garrido P, Valcárcel F Non-small-cell lung cancer (NSCLC) accounts for approximately 80%-85% of all cases of lung cancer; for patients with stage III disease, it accounts for approximately 40% of all cases. The treatment for unresectable stage III NSCLC is the combination of platinum-based chemotherapy and thoracic radiation. In this article, new targeted agents under investigation for possible integration into the combined therapy are reviewed. One of the most promising strategies is the inhibition of the epidermal growth factor receptor (EGFR) pathway. Radiation activates EGFR signaling, leading to radio-resistance by inducing cell proliferation and enhanced DNA repair. Several preclinical models have shown synergistic activity when cetuxima...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer.

Clinical Lung Cancer — Mon, 01 Mar 2010 00:00:00 +0100

Authors: Langer C, Soria JC Standard first-line therapy for non-small-cell lung cancer (NSCLC) with platinum-based agents, given in combination with cytotoxic compounds, has reached a relative plateau in its therapeutic efficacy. Novel molecular targeted agents acting on specific pathways have emerged as effective agents for treating NSCLC; some have already produced positive results in phase III trials. Notably, inhibition of the vascular endothelial growth factor (VEGF) pathway with an anti-VEGF antibody, bevacizumab, and targeting the epidermal growth factor receptor (EGFR) pathway with a small-molecule EGFR tyrosine kinase inhibitor erlotinib or a monoclonal antibody (cetuximab) have demonstrated prolonged survival in patients with advanced disease in both the first- and second-lin...

Avastin Phase III Study Shows Positive Results In Women With Advanced Ovarian Cancer

Health News from Medical News Today — Sat, 27 Feb 2010 10:00:00 +0100

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that a phase III study showed the combination of Avastin (bevacizumab) and chemotherapy followed by maintenance use of Avastin increased the time women with advanced ovarian cancer lived without their disease worsening (progression-free survival or PFS) compared to chemotherapy alone. A preliminary assessment of safety noted adverse events previously observed in pivotal trials with Avastin. Data from the study will be submitted for presentation at the 2010 American Society of Clinical Oncology (ASCO) annual meeting, June 4 to 8, 2010... (Source: Health News from Medical News Today)

Avastin Phase III Study Shows Positive Results In Women With Advanced Ovarian Cancer

Pharma Industry News From Medical News Today — Sat, 27 Feb 2010 10:00:00 +0100

Current Status and Problems in Development of Molecular Target Agents for Gastrointestinal Malignancy in Japan

Japanese Journal of Clinical Oncology — Fri, 26 Feb 2010 16:57:31 +0100

Since late 1990s, many molecular target agents have been introduced to clinical trials for various kinds of tumors, and some of them showing significant benefits have been approved. However, these global trials were mainly conducted outside Japan, and the ‘drag lag’ has been a serious problem in Japan recently. Nowadays, Japanese institutions have been participating in some global trials, and the drug lags are getting shorter. For colorectal cancer, molecular target agents such as bevacizumab and cetuximab have been approved in Japan, resulting in improved clinical outcomes. For gastric cancer, Japanese institutions not only contribute to the global Phase III trials of trastuzumab and bevacizumab but also show leadership in the early development of other new agents. For pancrea...

Intravitreal bevacizumab for choroidal neovascular membrane associated with Best's vitelliform dystrophy

Indian Journal of Ophthalmology — Fri, 26 Feb 2010 15:05:53 +0100

Rishi Ekta, Rishi Pukhraj, Mahajan SheshadriIndian Journal of Ophthalmology 2010 58(2):160-162Best's vitelliform macular dystrophy is a hereditary form of progressive macular dystrophy that can be complicated by choroidal neovascularization. Authors report successful treatment of choroidal neovascularization with intravitreal bevacizumab in one such eye in an 'adult' Indian male with visual improvement. A 23-year-old male presented with diminution of vision in the right eye for the past sixteen months. Visual acuity was 20/400 in the that eye. After three consecutive intravitreal injections of bevacizumab (1.25 mg/0.05 ml), vision improved to 20/120. Seven months following the last injection of bevacizumab, fundus appeared stable and visual acuity was maintained. No dr...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Pneumatic displacement and intravitreal bevacizumab for management of submacular hemorrhage in choroidal neovascular membrane

Indian Journal of Ophthalmology — Fri, 26 Feb 2010 15:05:53 +0100

Agarwal Manisha, Chaudhary S P, Narula Ritesh, Rajpal SimpyIndian Journal of Ophthalmology 2010 58(2):170-171 (Source: Indian Journal of Ophthalmology)

Avastin "treats ovarian cancer"

Pharmacy Europe — Fri, 26 Feb 2010 14:08:42 +0100

A drug designed to stop tumours developing blood vessels could help women with advanced ovarian cancer live longer, preliminary tests suggest. (Source: Pharmacy Europe)

Bevacizumab Slows Ovarian Cancer Progression

MedPage Today Hematology/Oncology — Fri, 26 Feb 2010 13:13:05 +0100

Maintenance therapy with bevacizumab (Avastin) following combination therapy with the drug and chemotherapy improved progression-free survival in women with previously untreated advanced ovarian cancer, drugmaker Genentech announced. (Source: MedPage Today Hematology/Oncology)

Genentech Announces Positive Results Of Avastin Phase III Study In Women With Advanced Ovarian Cancer

Health News from Medical News Today — Fri, 26 Feb 2010 06:00:00 +0100

Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that a Phase III study showed the combination of Avastin® (bevacizumab) and chemotherapy followed by maintenance use of Avastin alone increased the time women with previously untreated advanced ovarian cancer lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone. A preliminary assessment of safety noted adverse events previously observed in pivotal trials of Avastin... (Source: Health News from Medical News Today)

Genentech Announces Positive Results Of Avastin Phase III Study In Women With Advanced Ovarian Cancer

Cancer / Oncology News From Medical News Today — Fri, 26 Feb 2010 06:00:00 +0100

Genentech, Inc... (Source: Cancer / Oncology News From Medical News Today)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Pharmacokinetics of Bevacizumab and Its Effect on Vascular Endothelial Growth Factor after Intravitreal Injection of Bevacizumab in Macaque Eyes [Physiology and Pharmacology]

Investigative Ophthalmology — Fri, 26 Feb 2010 01:05:10 +0100

The authors evaluated the pharmacokinetics of bevacizumab and its effect against vascular endothelial growth factor (VEGF) after intravitreal injection of bevacizumab in cynomolgus macaques. Intravitreal injection of bevacizumab decreased VEGF levels in the treated eyes for at least 4 weeks and had no or a minimal effect on the untreated fellow eyes. (Source: Investigative Ophthalmology)

Phase III study of Avastin in advanced stomach cancer did not meet primary endpoint

World Pharma News — Fri, 26 Feb 2010 00:00:00 +0100

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the topline results from a global phase III trial investigating the use of Avastin (bevacizumab) in combination with Xeloda (capecitabine) or fluorouracil and cisplatin chemotherapy in patients with inoperable, advanced or metastatic gastric cancer (stomach cancer). (Source: World Pharma News)

Genentech: Avastin strong in ovarian cancer trial

bizjournals.com Health Care:Biotechnology headlines — Thu, 25 Feb 2010 22:13:33 +0100

Genentech Inc.’s cancer drug Avastin helped ovarian cancer patients live longer without the disease worsening, according to a preliminary assessment of a Phase III trial. (Source: bizjournals.com Health Care:Biotechnology headlines)

Genentech Announces Positive Results of Avastin Phase III Study in Women with Advanced Ovarian Cancer

Drugs.com - Clinical Trials — Thu, 25 Feb 2010 14:06:07 +0100

First Phase III Study of an Anti-Angiogenic Therapy in Advanced Ovarian Cancer to Meet Primary Endpoint SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb 25, 2010 - Genentech, Inc., a wholly owned member of the Roche... (Source: Drugs.com - Clinical Trials)

Genentech Announces Positive Results of Avastin Phase III Study in Women with Advanced Ovarian Cancer

HSMN NewsFeed — Thu, 25 Feb 2010 13:19:12 +0100

First Phase III Study of an Anti-Angiogenic Therapy in Advanced Ovarian Cancer to Meet Primary Endpoint SOUTH SAN FRANCISCO, Calif.--(HSMN NewsFeed)--Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced... Biopharmaceuticals, OncologyGenentech, Roche Group, Avastin, bevacizumab, ovarian cancer (Source: HSMN NewsFeed)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Roche's Avastin helps in ovarian cancer

Reuters: Health — Thu, 25 Feb 2010 10:04:33 +0100

ZURICH (Reuters) - Roche's Avastin helps women with advanced ovarian cancer live longer without their disease getting worse, a late-stage study showed, boosting its prospects after a recent setback in stomach cancer. (Source: Reuters: Health)

Avastin Shows Positive Results in Ovarian Cancer

WSJ.com: Health — Thu, 25 Feb 2010 09:58:26 +0100

Roche said its cancer drug Avastin showed positive results in the treatment of advanced ovarian cancer, further improving the prospects of one of the Swiss pharmaceutical company's best-selling drugs. (Source: WSJ.com: Health)

Intravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion

Graefe's Archive for Clinical and Experimental Ophthalmology — Thu, 25 Feb 2010 06:52:27 +0100

Conclusions IVTA and IVB injections were similarly effective for improving visual acuity in patients with macular edema secondary to BRVO. However, the IVTA group showed longer mean improvement duration and less disease recurrence, and required fewer injections than the IVB group. Content Type Journal ArticleCategory Retinal DisordersDOI 10.1007/s00417-010-1320-2Authors Yeo Jue Byun, Yonsei University College of Medicine The Institute of Vision Research, Department of Ophthalmology 134 Shinchon-dong, Sodaemoon-gu Seoul 120-752 KoreaMi In Roh, Yonsei University College of Medicine The Institute of Vision Research, Department of Ophthalmology 134 Shinchon-dong, Sodaemoon-gu Seoul 120-752 KoreaSung Chul Lee, Yonsei University College of Medicine The Institute of Vision...

Avastin phase III study shows positive results in women with advanced ovarian cancer

Roche Media News — Thu, 25 Feb 2010 06:00:00 +0100

Roche announced today that a phase III study showed the combination of Avastin (bevacizumab) and chemotherapy followed by maintenance use of Avastin increased the time women with advanced ovarian cancer lived without their disease worsening (progression-free survival or PFS) compared to chemotherapy alone. A preliminary assessment of safety noted adverse events previously observed in pivotal trials with Avastin. Data from the study will be submitted for presentation at the 2010 American Society of Clinical Oncology (ASCO) annual meeting, June 4 to 8, 2010. (Source: Roche Media News)

Avastin phase III study shows positive results in women with advanced ovarian cancer

Roche Investor Update — Thu, 25 Feb 2010 06:00:00 +0100

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Protective Effect of Intravitreal Bevacizumab and Sub-Tenon Triamcinolone Acetonide against Occlusion of Choriocapillaris Induced by Photodynamic Therapy

Ophthalmologica — Wed, 24 Feb 2010 23:00:00 +0100

Ophthalmologica 2010;224:267273 (DOI:10.1159/000287348) (Source: Ophthalmologica)

Genentech Announces Positive Results Of Avastin Phase III Study In Women With Advanced Ovarian Cancer

Pharmaceutical Online News — Wed, 24 Feb 2010 07:22:00 +0100

Genentech, Inc., a wholly owned member of the Roche Group, recently announced that a Phase III study showed the combination of Avastin (bevacizumab) and chemotherapy followed by maintenance use of Avastin alone increased the time women with previously untreated advanced ovarian cancer lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone. (Source: Pharmaceutical Online News)

Phase III Study Of Avastin Plus Chemotherapy In Advanced Stomach Cancer Did Not Meet Primary Endpoint

Health News from Medical News Today — Wed, 24 Feb 2010 07:00:00 +0100

Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing Avastin® (bevacizumab) plus Xeloda® (capecitabine) or 5-FU and cisplatin chemotherapy extended the lives of people with inoperable or advanced stomach (gastric) cancer, compared to chemotherapy alone. Adverse events in the trial were consistent with those previously reported for Avastin and no new safety signals have been observed to date... (Source: Health News from Medical News Today)

Phase III Study Of Avastin Plus Chemotherapy In Advanced Stomach Cancer Did Not Meet Primary Endpoint

Cancer / Oncology News From Medical News Today — Wed, 24 Feb 2010 07:00:00 +0100

Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing Avastin® (bevacizumab) plus Xeloda® (capecitabine) or 5-FU and cisplatin chemotherapy extended the lives of people with inoperable or advanced stomach (gastric) cancer, compared to chemotherapy alone... (Source: Cancer / Oncology News From Medical News Today)

Effects of intravitreal bevacizumab treatment on proliferative retinopathy in a patient with cerebroretinal vasculopathy

Journal of Neurology — Wed, 24 Feb 2010 06:48:24 +0100

Content Type Journal ArticleCategory Letter to the editorsDOI 10.1007/s00415-010-5500-0Authors Marcus Kernt, Ludwig Maximilian University Department of Ophthalmology Mathildenstr. 8 80336 Munich GermanyAndreas Gschwendtner, Ludwig Maximilian University Department of Neurology Munich GermanyAljoscha S. Neubauer, Ludwig Maximilian University Department of Ophthalmology Mathildenstr. 8 80336 Munich GermanyMartin Dichgans, Ludwig Maximilian University Department of Neurology Munich GermanyChristos Haritoglou, Ludwig Maximilian University Department of Ophthalmology Mathildenstr. 8 80336 Munich Germany Journal Journal of NeurologyOnline ISSN 1432-1459Print ISSN 0340-5354 (Source: Journal of Neurology)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Update on systemic therapies of metastatic renal cell carcinoma

World Journal of Urology — Wed, 24 Feb 2010 06:47:59 +0100

Conclusions A range of potent drugs are available to patients with metastatic RCC. Treatment decisions should be made carefully taking into consideration that all targeted agents only have a palliative effect with prolongation of life, but do not cure metastatic RCC. Content Type Journal ArticleCategory Topic PaperDOI 10.1007/s00345-010-0519-5Authors E. Herrmann, University of Münster Department of Urology Albert-Schweitzer Strasse 33 48149 Münster GermanyS. Bierer, University of Münster Department of Urology Albert-Schweitzer Strasse 33 48149 Münster GermanyC. Wülfing, University of Münster Department of Urology Albert-Schweitzer Strasse 33 48149 Münster Germany Journal World Journal of UrologyOnline ISSN 1433-8726Print ISSN 0724-4983 (Source: World J...

Phase III study of bevacizumab plus chemotherapy in advanced gastric cancer fails to meet primary endpoint

NeLM - News — Wed, 24 Feb 2010 00:00:00 +0100

Source: BioSpace Area: News According to a report featured by BioSpace, AVAGAST, a phase III study evaluating the effect of bevacizumab and capecitabine or 5-FU and cisplatin chemotherapy compared to capecitabine or 5-FU and cisplatin chemotherapy alone in 774 patients with gastric cancer, did not meet its primary endpoint of improved overall survival. Data from the study will be submitted for presentation at the 2010 American Society of Clinical Oncology (ASCO) annual meeting, June 4 to 8, 2010. (Source: NeLM - News)

Genentech's Avastin fails stomach cancer trial

bizjournals.com Health Care:Biotechnology headlines — Tue, 23 Feb 2010 17:32:21 +0100

Genentech Inc.’s tumor-starving drug Avastin failed a late-stage trial in stomach cancer patients that could shave $400 million or more from parent company Roche’s long-term sales forecast. (Source: bizjournals.com Health Care:Biotechnology headlines)

Phase III Study of Avastin Plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary Endpoint

Drugs.com - Clinical Trials — Tue, 23 Feb 2010 14:25:21 +0100

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb 23, 2010 - Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing... (Source: Drugs.com - Clinical Trials)

Phase III Study of Avastin Plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary Endpoint

HSMN NewsFeed — Tue, 23 Feb 2010 12:27:19 +0100

SOUTH SAN FRANCISCO, Calif.--(HSMN NewsFeed)--Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing Avastin® (bevacizumab) p... Biopharmaceuticals, OncologyGenentech, Roche Group, Avastin, bevacizumab, stomach cancer (Source: HSMN NewsFeed)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Roche, Genentech Report Avastin Study Failure

Drugs.com - Pharma News — Tue, 23 Feb 2010 12:20:50 +0100

From Associated Press (February 23, 2010) NEW YORK -- Genentech said Tuesday the combination of its blockbuster cancer drug Avastin and Xeloda did not meet a late-stage study goal of extending the lives of advanced stomach cancer patients. The... (Source: Drugs.com - Pharma News)

Roche's Avastin fails in stomach cancer trial

Reuters: Health — Tue, 23 Feb 2010 09:13:47 +0100

ZURICH (Reuters) - Roche Holding's cancer drug Avastin missed its main target in a late-stage trial when used with chemotherapy to treat patients with advanced stomach cancer, the Swiss drugmaker said on Tuesday. (Source: Reuters: Health)

Vascular Endothelial Growth Factor Polymorphisms: Role in Response and Toxicity of Tyrosine Kinase Inhibitors

Current Oncology Reports — Tue, 23 Feb 2010 08:08:12 +0100

Abstract Angiogenesis is central to the growth of normal tissues and tumors. Inhibiting this pathway has been a strategy for drug development for tumors not responsive to most agents used in chemotherapy. Notably, signaling mediated by vascular endothelial growth factor (VEGF) is a key target because aberrant signaling via this pathway is frequently associated with neoangiogenesis in tumors. The drug-discovery effort to blunt VEGF signaling has led to the approval of bevacizumab and several receptor tyrosine kinase inhibitors (TKIs) that have shown efficacy in the clinical management of breast, colorectal, lung, and kidney cancer. Understanding the genetic variability in VEGF and VEGF receptor has led to identifying genotypic variations (single nucleotide polymorphisms [SN...

Bevacizumab Improves Pathological Response of Colorectal Cancer Liver Metastases Treated with XELOX/FOLFOX

Annals of Surgical Oncology — Tue, 23 Feb 2010 07:57:32 +0100

Conclusions Classifying histological response based on tumor regression grades qualifies to predict the outcome of patients with colorectal cancer liver metastases. Tumor regression grading provides a standardized pathological response evaluation, against which radiologic response on chemotherapy including biologicals can be prospectively evaluated. Content Type Journal ArticleCategory Colorectal CancerDOI 10.1245/s10434-010-0972-9Authors Markus Klinger, Medical University of Vienna Department of General Surgery, Hepatobiliary Service Vienna AustriaDietmar Tamandl, Medical University of Vienna Department of General Surgery, Hepatobiliary Service Vienna AustriaSandra Eipeldauer, Medical University of Vienna Clinical Institute of Pathology Vienna AustriaStefan Hacker,...

Combined phacoemulsification and viscogoniosynechialysis in the management of patients with chronic angle closure glaucoma

International Ophthalmology — Tue, 23 Feb 2010 07:47:39 +0100

Abstract The purpose of this study was to evaluate the effectiveness of phacoemulsification and viscogoniosynechialysis in the management of patients with chronic angle-closure glaucoma (CACG). Fifty-six eyes of 45 recruited patients were classified into two groups: group 1 had medically controlled CACG (IOP ≤ 21 mmHg) comprising 35 eyes and group 2 medically uncontrolled CACG (IOP > 21 mmHg with maximum tolerated medications) including 21 eyes. All of the patients had at least one quadrant without peripheral anterior synechia in gonioscopy. After phacoemulsification, a viscoelastic agent was used for viscogoniasynecialysis. Success was defined as IOP ≤ 21 mmHg with (relative success) or without (absolute success) medicati...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Roche, Genentech report study failure for Avastin combination aimed at stomach cancer

OrlandoSentinel: Medical Research — Tue, 23 Feb 2010 07:35:00 +0100

NEW YORK (AP) — Genentech said Tuesday the combination of its blockbuster cancer drug Avastin and Xeloda did not meet a late-stage study goal of extending the lives of advanced stomach cancer patients. The company, a unit of Switzerland's Roche,... (Source: OrlandoSentinel: Medical Research)

Avastin misses target for advanced stomach cancer

Reuters: Health — Tue, 23 Feb 2010 06:49:18 +0100

ZURICH (Reuters) - Roche Holding AG's cancer drug Avastin missed its main target in a late-stage trial when used with chemotherapy to treat patients with advanced stomach cancer, the Swiss drugmaker said on Tuesday. (Source: Reuters: Health)

Phase III study of Avastin plus chemotherapy in advanced stomach cancer did not meet primary endpoint

Roche Media News — Tue, 23 Feb 2010 06:00:00 +0100

Roche announced today the topline results from a global phase III trial investigating the use of Avastin (bevacizumab) in combination with Xeloda (capecitabine) or fluorouracil and cisplatin chemotherapy in patients with inoperable, advanced or metastatic gastric cancer (stomach cancer). The study, known as AVAGAST, did not meet its primary endpoint of extending overall survival in patients treated with Avastin in combination with chemotherapy compared to the same chemotherapy plus placebo. (Source: Roche Media News)

Phase III study of Avastin plus chemotherapy in advanced stomach cancer did not meet primary endpoint

Roche Investor Update — Tue, 23 Feb 2010 06:00:00 +0100

Clinical course of advanced NSCLC patients experiencing hypertension during treatment with bevacizumab (ECOG 4599)

NeLM - News — Tue, 23 Feb 2010 00:00:00 +0100

Source: JCO Area: News According to research published in the Journal of clinical Oncology, the onset of high blood pressure (HBP) during treatment with bevacizumab in combination with carboplatin and paclitaxel (PCB) may be associated with improved clinical outcomes among patients with advanced non-squamous non-small-cell lung cancer (NSCLC). Because bevacizumab is postulated to decrease nitric oxide synthesis, leading to hypertension, which in turn may be a physiological sign that the VEGF pathway is more actively being blocked researchers evaluated whether patients showing signs of hypertension would be more likely to derive improved outcomes. The ECOG 4599 was a phase III trial in which patients (n = 878) with advanced non-squamous NSCLC were randomly assigned to...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

[Management of metastatic HER2-positive breast cancer: present and future.]

Bulletin du Cancer — Tue, 23 Feb 2010 00:00:00 +0100

Authors: Guiu S, Coudert B, Favier L, Arnould L, Fumoleau P HER2-positive breast cancer accounts for 20 to 25% of breast cancers. The surexpression of this tyrosine-kinase receptor is often associated with a poor prognosis. However, the management and the outcome of these patients have changed these last ten years with trastuzumab. Despite the encouraging results obtained with this humanized monoclonal antibody directed against the HER2-receptor, used alone or in association with chemotherapy in metastatic patients, progression under trastuzumab are usually observed and resistances to this treatment are described. Thus, many other monoclonal antibodies and tyrosine-kinase inhibitors emerged. These therapeutics, used alone or in association with chemotherapy or trastuzumab have variable...

Lestaurtinib Enhances the Antitumor Efficacy of Chemotherapy in Murine Xenograft Models of Neuroblastoma.

Clinical Cancer Research — Tue, 23 Feb 2010 00:00:00 +0100

CONCLUSIONS: We show that lestaurtinib can inhibit the growth of neuroblastoma both in vitro and in vivo and can substantially enhance the efficacy of conventional chemotherapy, presumably by inhibition of the Trk/brain-derived neurotrophic factor autocrine survival pathway. It may also enhance the efficacy of selected biological agents, but further testing is required to rule out unanticipated toxicities. Our data support the incorporation of Trk inhibitors, such as lestaurtinib, in clinical trials of neuroblastoma or other tumors relying on Trk signaling pathways for survival. Clin Cancer Res; 16(5); 1478-85. PMID: 20179224 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)

Comparative Profiling of the Novel Epothilone, Sagopilone, in Xenografts Derived from Primary Non-Small Cell Lung Cancer.

Clinical Cancer Research — Tue, 23 Feb 2010 00:00:00 +0100

CONCLUSION: Analyses provided here show how preclinical studies can provide hypotheses for the identification of patients who more likely will benefit from new drugs as well as a rationale for combination therapies to be tested in clinical trials. Clin Cancer Res; 16(5); 1452-65. PMID: 20179216 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)

Bevacizumab: Colon perforation: 2 case reports

Reactions — Mon, 22 Feb 2010 14:16:47 +0100

(Source: Reactions)

Second-line bevacizumab plus chemo improves PFS

Cancer Network — Mon, 22 Feb 2010 12:00:00 +0100

The RIBBON-2 trial met its primary endpoint of prolonged progression-free survival. (Source: Cancer Network)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Bevacizumab Reduces Nose Bleeds in Inherited Condition

Modern Medicine — Mon, 22 Feb 2010 00:00:00 +0100

The vascular endothelial growth factor inhibitor bevacizumab administered by intranasal injection, or even by topical nasal spray, can effectively treat epistaxis from hereditary hemorrhagic telangiectasia, according to reports published in The Laryngoscope. (Source: Modern Medicine)

Bevacizumab-induced hand-foot syndrome: circumscribed type.

The British Journal of Dermatology — Mon, 22 Feb 2010 00:00:00 +0100

Authors: Munehiro A, Yoneda K, Nakai K, Demitsu T, Moriue T, Moriue J, Yokoi I, Fujita N, Matsuura N, Ishikawa S, Kubota Y PMID: 20184580 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)

Choroidal Neovascularization in Pathologic Myopia: Intravitreal Ranibizumab Versus Bevacizumab—A Randomized Controlled Trial

American Journal of Ophthalmology — Sat, 20 Feb 2010 15:05:21 +0100

Conclusion: This randomized clinical study cannot determine a statistically significant difference in anti-VEGF treatment effect between ranibizumab and bevacizumab for the treatment of CNV secondary to pathologic myopia. A larger study is required to determine the relative efficacy and duration of action of these drugs. (Source: American Journal of Ophthalmology)

A review of clinical trials of anti-VEGF agents for diabetic retinopathy

Graefe's Archive for Clinical and Experimental Ophthalmology — Sat, 20 Feb 2010 06:50:18 +0100

Conclusions For diabetic macular edema, phase II trials of intravitreal pegaptanib and intravitreal ranibizumab have shown short-term benefit in visual acuity. Intravitreal bevacizumab also has been shown to have beneficial short-term effects on both visual acuity and retinal thickness. For proliferative diabetic retinopathy (PDR), early studies suggest that intravitreal bevacizumab temporarily decreases leakage from diabetic neovascular lesions, but this treatment may be associated with tractional retinal detachment (TRD). Furthermore, several studies indicate that bevacizumab is likely to prove a helpful adjunct to diabetic pars plana vitrectomy (PPV) for TRD. Finally, three small series suggest a potential beneficial effect of a single dose of bevacizumab to prevent wor...

Scientists At University of Texas Cancer Center Publish Research In Colon Cancer Therapy

Cancercompass News: Colorectal Cancer — Fri, 19 Feb 2010 00:00:00 +0100

A report, 'The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development,' is newly published data in The Oncologist. "Targeted biologic agents have an established role in treating metastatic colorectal cancer (mCRC). Bevacizumab, a recombinant monoclonal antibody against the vascular endothelial growth factor ligand is approved by the U.S.," scientists in the United States report. (Source: Cancercompass News: Colorectal Cancer)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

[Hepatotoxicity of metastatic colorectal cancer chemotherapy: systematic review.]

Bulletin du Cancer — Fri, 19 Feb 2010 00:00:00 +0100

ConclusionThe fact that irinotecan may be linked to an increased risk of hepatic failure and postoperative death, which is not the case of oxaliplatine, must be took in consideration in the choice of the preoperative chemotherapy before resection of hepatic metastasis of colorectal cancer. PMID: 20167564 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)

[Mechanisms of resistance to molecular targeted therapies in breast cancer: update and future.]

Bulletin du Cancer — Fri, 19 Feb 2010 00:00:00 +0100

Authors: Magné N, Chargari C, Conforti R, Toillon RA, Bauduceau O, Védrine L, Khayat D, Spano JP The importance of targeted therapies has been emphasized by clinical trials using antiangiogenic or HER2 inhibitors in breast cancer. First with trastuzumab, it was demonstrated that targeted therapies may improve outcome in patients with HER overexpressing breast cancer in metastatic or adjuvant settings. The emerging role for angiogenesis inhibitors has also been demonstrated with bevacizumab. Unfortunately, there is growing clinical and biological evidence that tumour cells may develop unexpected and complex mechanisms of resistance to those targeted therapies. This review outlines the mechanisms by which tumour cells may resist to new targeted agents. Most recent developments ...

Diffusion Magnetic Resonance Imaging Detects Pathologically Confirmed, Nonenhancing Tumor Progression in a Patient With Recurrent Glioblastoma Receiving Bevacizumab [DIAGNOSIS IN ONCOLOGY]

Journal of Clinical Oncology — Thu, 18 Feb 2010 23:00:38 +0100

(Source: Journal of Clinical Oncology)

Clinical Course of Advanced Non-Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599 [Thoracic Oncology]

Journal of Clinical Oncology — Thu, 18 Feb 2010 23:00:37 +0100

Conclusion Data from ECOG 4599 suggest that onset of HBP during treatment with PCB may be associated with improved outcomes, and additional studies of the downstream effects of VEGF suppression and hypertension are needed. (Source: Journal of Clinical Oncology)

Effects of Bevacizumab on Apoptosis, Na + -K + -Adenosine Triphosphatase and Zonula Occludens 1 Expression on Cultured Corneal Endothelial Cells

Ophthalmic Research — Thu, 18 Feb 2010 23:00:00 +0100

Ophthalmic Res 2010;44:4349 (DOI:10.1159/000286339) (Source: Ophthalmic Research)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Intracellular bevacizumab reduces phagocytotic uptake in RPE cells

Graefe's Archive for Clinical and Experimental Ophthalmology — Thu, 18 Feb 2010 17:54:26 +0100

Conclusions The uptake of bevacizumab reduces phagocytosis in RPE cells, which indicates possible long-term effects of repeated bevacizumab treatment. Content Type Journal ArticleCategory Basic ScienceDOI 10.1007/s00417-010-1317-xAuthors Alexa Klettner, University of Kiel, Department of Ophthalmology Arnold-Heller-Str. 3, Haus 25 24105 Kiel GermanyFriederike Möhle, University of Kiel, Department of Ophthalmology Arnold-Heller-Str. 3, Haus 25 24105 Kiel GermanyJohann Roider, University of Kiel, Department of Ophthalmology Arnold-Heller-Str. 3, Haus 25 24105 Kiel Germany Journal Graefe's Archive for Clinical and Experimental OphthalmologyOnline ISSN 1435-702XPrint ISSN 0721-832X (Source: Graefe's Archive for Clinical and Experimental Ophthalmology)

Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization associated with large retinal pigment epithelial detachment in age-related macular degeneration

Graefe's Archive for Clinical and Experimental Ophthalmology — Thu, 18 Feb 2010 17:54:24 +0100

Conclusion Combined IVB and IVTA therapy seems to be an effective and safe procedure to treat CNV associated with large PED in AMD. Content Type Journal ArticleCategory Retinal DisordersDOI 10.1007/s00417-010-1302-4Authors Leila el Matri, Hedi Rais Institute of Ophthalmology Department B of Ophthalmology Boulevard 9 avril 1006 Bab saadoun Tunis TunisiaAhmed Chebil, Hedi Rais Institute of Ophthalmology Department B of Ophthalmology Boulevard 9 avril 1006 Bab saadoun Tunis TunisiaFadra Kort, Hedi Rais Institute of Ophthalmology Department B of Ophthalmology Boulevard 9 avril 1006 Bab saadoun Tunis TunisiaRym Bouraoui, Hedi Rais Institute of Ophthalmology Department B of Ophthalmology Boulevard 9 avril 1006 Bab saadoun Tunis TunisiaKarim Baklouti, Hedi Rais Institute of Op...

Comparison of Intravitreal Bevacizumab versus Triamcinolone for the Treatment of Diffuse Diabetic Macular Edema

Ophthalmologica — Tue, 16 Feb 2010 23:00:00 +0100

Ophthalmologica 2010;224:258264 (DOI:10.1159/000284466) (Source: Ophthalmologica)

Concentrations of unbound bevacizumab in the aqueous of untreated fellow eyes after a single intravitreal injection in humans

Acta Ophthalmologica — Tue, 16 Feb 2010 00:00:00 +0100

Conclusions: There are no pharmacological indications for a significant concentration of unbound bevacizumab in the anterior chamber of contralateral eyes in humans. (Source: Acta Ophthalmologica)

Microperimetric changes after intravitreal bevacizumab injection for exudative age-related macular degeneration

Acta Ophthalmologica — Tue, 16 Feb 2010 00:00:00 +0100

Conclusion: Intravitreal bevacizumab therapy induced a significant increase in mean retinal sensitivity and significant decrease in mean absolute scotoma size during 6 months. The MP1 microperimetry proved to be a valuable tool in the evaluation of functional benefit of exudative AMD therapy with intravitreal bevacizumab. (Source: Acta Ophthalmologica)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials.

Acta Oncologica — Tue, 16 Feb 2010 00:00:00 +0100

Discussion. Treatment with bevacizumab may significantly increase the risk of cardiac ischemic events in cancer patients. PMID: 20156114 [PubMed - as supplied by publisher] (Source: Acta Oncologica)

Bevacizumab as a treatment option in advanced renal cell carcinoma: An analysis and ...

UroToday — Mon, 15 Feb 2010 23:00:00 +0100

Beth Israel Deaconess Medical Center, Department of Medicine, Division of Hematology/Oncology, 375 Longwood Avenue, MS 428, Boston, MA 02215,... (Source: UroToday)

Bevacizumab: Thrombocytopenia during single-agent therapy: case report

Reactions — Mon, 15 Feb 2010 14:06:03 +0100

(Source: Reactions)

The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer

Journal of Cancer Research and Clinical Oncology — Sat, 13 Feb 2010 06:46:50 +0100

Conclusion Non-significant changes in apoptotic markers with bevacizumab-based chemotherapy showed that they have no prognostic significance in MCRC patients. Significant change in sFAS/sFASL ratio according to treatment response could be an indicator of chemosensitivity. Content Type Journal ArticleCategory Original PaperDOI 10.1007/s00432-010-0803-1Authors Ramazan Yildiz, Gazi University Faculty of Medicine Department of Medical Oncology Besevler Ankara 06500 TurkeyMustafa Benekli, Gazi University Faculty of Medicine Department of Medical Oncology Besevler Ankara 06500 TurkeySuleyman Buyukberber, Gazi University Faculty of Medicine Department of Medical Oncology Besevler Ankara 06500 TurkeyAli Osman Kaya, Gazi University Faculty of Medicine Department of Medical Onco...

An Advance in Therapy for Patients With NSCLC

Medscape Today Headlines — Fri, 12 Feb 2010 23:09:08 +0100

Does bevacizumab combined with pemetrexed and cisplatin provide improved efficacy in the treatment of non-small-cell lung cancer? Dr. Mark Kris examines the literature and answers this question. Medscape Hematology-Oncology (Source: Medscape Today Headlines)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

New Treatment For Chronic Nose Bleeds

Health News from Medical News Today — Fri, 12 Feb 2010 10:00:00 +0100

Patients suffering from hereditary hemorrhagic telangiectasia (HHT), an inherited vascular condition characterized by profuse nosebleeds, may find hope in a cancer-fighting drug called bevacizumab, also known as Avastin. "Bevacizumab is a drug used to treat cancers and eye disorders by restricting the growth of abnormal blood vessels," said Terence M. Davidson, MD, professor of surgery and director of the UC San Diego Nasal Dysfunction Clinic... (Source: Health News from Medical News Today)

New Treatment For Chronic Nose Bleeds

Ear, Nose and Throat News From Medical News Today — Fri, 12 Feb 2010 10:00:00 +0100

Patients suffering from hereditary hemorrhagic telangiectasia (HHT), an inherited vascular condition characterized by profuse nosebleeds, may find hope in a cancer-fighting drug called bevacizumab, also known as Avastin. "Bevacizumab is a drug used to treat cancers and eye disorders by restricting the growth of abnormal blood vessels," said Terence M... (Source: Ear, Nose and Throat News From Medical News Today)

Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma

Journal of Neuro-Oncology — Fri, 12 Feb 2010 07:09:58 +0100

Abstract After withdrawal of bevacizumab in patients with recurrent high-grade glioma, we have observed a rapid tumour re-growth or “rebound” radiographic phenomenon with accelerated clinical decline. We retrospectively reviewed 11 patients treated at the Henry Ford Hermelin Brain Tumor Center with recurrent high-grade glioma who demonstrated a rebound progression pattern after the discontinuation of bevacizumab. The original tumour area-of-enhancement increased by a mean of 158%, when compared to the rebound magnetic resonance imaging. After rebound, no patients (0/8) showed a response to next-line treatments that did not include bevacizumab. The median survival of those re-treated with bevacizumab was 149 and 32 days for those who received other regimens. Abrupt...

Aqueous Humor Concentration of Bevacizumab After Subconjunctival Injection in Rabbit

Journal of Ocular Pharmacology and Therapeutics — Thu, 11 Feb 2010 18:19:39 +0100

Journal of Ocular Pharmacology and Therapeutics , Vol. 0, No. 0. (Source: Journal of Ocular Pharmacology and Therapeutics)

Long-Term Follow-Up After Multiple Intravitreal Bevacizumab Injections for Exudative Age-Related Macular Degeneration

Journal of Ocular Pharmacology and Therapeutics — Thu, 11 Feb 2010 18:15:59 +0100

Journal of Ocular Pharmacology and Therapeutics , Vol. 0, No. 0. (Source: Journal of Ocular Pharmacology and Therapeutics)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Intravitreal Bevacizumab (Avastin) in the Treatment of Macular Edema Associated With Perfused Retinal Vein Occlusion

Journal of Ocular Pharmacology and Therapeutics — Thu, 11 Feb 2010 18:10:30 +0100

Journal of Ocular Pharmacology and Therapeutics , Vol. 0, No. 0. (Source: Journal of Ocular Pharmacology and Therapeutics)

Adjunctive Intravitreal Bevacizumab-Combined Trabeculectomy Versus Trabeculectomy Alone in the Treatment of Neovascular Glaucoma

Journal of Ocular Pharmacology and Therapeutics — Thu, 11 Feb 2010 17:16:01 +0100

Journal of Ocular Pharmacology and Therapeutics , Vol. 0, No. 0. (Source: Journal of Ocular Pharmacology and Therapeutics)

Bevacizumab (Avastin) [PHARMACOLOGY VIGNETTE]

American Journal of Neuroradiology — Thu, 11 Feb 2010 16:01:13 +0100

SUMMARY: Bevacizumab is a humanized monoclonal antibody that was the first FDA approved therapy designed to inhibit angiogenesis. This paper will review the mechanism of action and clinical role of this antiangiogenic agent. (Source: American Journal of Neuroradiology)

Conjugation of bevacizumab to cationic liposomes enhances their tumor-targeting potential

Future Medicine: Nanomedicine — Thu, 11 Feb 2010 13:41:02 +0100

Nanomedicine , February 2010, Vol. 5, No. 2, Pages 181-192. (Source: Future Medicine: Nanomedicine)

Safety and Efficacy of First-line Bevacizumab With FOLFOX, XELOX, FOLFIRI and Fluoropyrimidines in Metastatic Colorectal Cancer: The BEAT Study

Medscape Today Headlines — Thu, 11 Feb 2010 11:10:18 +0100

The Bevacizumab Expanded Access Trial (BEAT) evaluated the safety and efficacy of bevacizumab plus first-line chemotherapy in a general cohort of patients with metastatic colorectal cancer. Annals of Oncology (Source: Medscape Today Headlines)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL).

Ann Oncol — Thu, 11 Feb 2010 00:00:00 +0100

CONCLUSIONS: Final analysis of AVAiL confirms the efficacy of bevacizumab when combined with cisplatin-gemcitabine. The PFS benefit did not translate into a significant OS benefit, possibly due to high use of efficacious second-line therapies. PMID: 20150572 [PubMed - as supplied by publisher] (Source: Ann Oncol)

Bevacizumab: Nonarteritic anterior ischaemic optic neuropathy following intravitreal administration: case report

Reactions — Wed, 10 Feb 2010 14:08:42 +0100

(Source: Reactions)

Bevacizumab: Intestinal perforation and peritonitis: 4 case reports

Reactions — Wed, 10 Feb 2010 14:08:42 +0100

(Source: Reactions)

Bevacizumab May Benefit Choroidal Neovascularization

Modern Medicine — Tue, 09 Feb 2010 00:00:00 +0100

Intravitreal bevacizumab treatment produces superior results in treating juxtafoveal choroidal neovascularization secondary to pathologic myopia compared with laser treatment and photodynamic therapy, according to a pilot study published online Feb. 8 in the Archives of Ophthalmology. (Source: Modern Medicine)

[Delayed anastomotic dehiscence in advanced colorectal cancer treated with Bevacizumab.]

Cirugia eEspanola — Tue, 09 Feb 2010 00:00:00 +0100

Authors: Placer C, Markinez I, Rodríguez A, Elósegui JL, Navascués JM PMID: 20149351 [PubMed - as supplied by publisher] (Source: Cirugia eEspanola)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Laser Photocoagulation, Photodynamic Therapy, and Intravitreal Bevacizumab for the Treatment of Juxtafoveal Choroidal Neovascularization Secondary to Pathologic Myopia [Clinical Sciences]

Archives of Opthalmology — Mon, 08 Feb 2010 20:43:21 +0100

Conclusions Overall, bevacizumab treatment offers the best functional results during a 2-year follow-up. In view of the small size of the sample in this study and the relatively low frequency of juxtafoveal choroidal neovascularization secondary to pathologic myopia, a multicentric clinical trial is necessary to validate our results.Published online February 8, 2010 (doi:10.1001/archophthalmol.2009.408). (Source: Archives of Opthalmology)

Avoiding Blood Clots During Treatment

About.com Colon Cancer — Mon, 08 Feb 2010 00:00:00 +0100

One of the potential side effects of some types of chemotherapy is blood clots. Blood clots should be taken very seriously. If a blood clot occurs in an area of the body supplying blood to a vital organ, such as the lungs or brain, it can be life threatening. Some people are given blood thinners during treatment, specifically to head off a blood clot before it occurs. Fortunately, these medications are very effective. If you are taking blood thinners as part of your cancer care, you should take these medications exactly as prescribed. Bevacizumab + ESA = More Blood Clots New research has now identified a specific combination of cancer treatment medications that may increase the risk of blood clots. This is very important information. It can help your doctor determine whether you are at hig...

Pattern electroretinogram changes after intravitreal bevacizumab injection for diabetic macular edema

Documenta Ophthalmologica — Sat, 06 Feb 2010 18:03:01 +0100

Abstract We aimed at investigating the efficacy of intravitreal bevacizumab injection by evaluation of pattern electroretinogram (PERG) in diabetic patients with clinically significant macular edema (CSME). Thirty-five eyes of 35 patients with diabetes were treated with 2.5 mg of intravitreal bevacizumab injection as the primary therapy for CSME. The main outcome measures included best-corrected visual acuity, fundus fluorescein angiography, and P50 amplitudes of pattern electroretinogram (PERG) before and after intravitreal injection. Mean visual acuity improved significantly from a mean LogMAR value of 1.1 ± 0.2 at baseline to a maximum of 0.7 ± 0.3 after a mean follow-up time of 6.4 months. The mean baseline P50 and N95 amplitudes of PERG ...

Interstitial Pneumonitis after Treatment with Bevacizumab and Pegylated Liposomal Doxorubicin in a Patient with Metastatic Breast Cancer

Chemotherapy — Sat, 06 Feb 2010 13:45:50 +0100

Chemotherapy 2010;56:6970 (DOI:10.1159/000282286) (Source: Chemotherapy)

Bevacizumab: When Is It Contraindicated in NSCLC Patients?

Medscape Today Headlines — Fri, 05 Feb 2010 22:11:15 +0100

Patient selection for bevacizumab therapy has changed since its FDA approval. In this video blog, Dr. Mark Kris addresses the absolute and relative contraindications to the use of this drug. Medscape Hematology-Oncology (Source: Medscape Today Headlines)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study

British Journal of Ophthalmology — Fri, 05 Feb 2010 09:33:15 +0100

Conclusions Combination bevacizumab and 25 J/cm2 or 12 J/cm2 PDT significantly reduced the number of bevacizumab treatments required over 6 months. This study was powered to examine number of treatments, but not visual acuities. Nevertheless, visual acuities responded favourably in all three groups. Further studies will be helpful to explore visual outcomes. (Source: British Journal of Ophthalmology)

Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration

British Journal of Ophthalmology — Fri, 05 Feb 2010 09:33:15 +0100

Conclusion The combination of IVB with low fluence PDT for the treatment of classic or predominantly classic neovascular AMD works in a synergistic fashion with a significant reduction in IVB reinjections rate. (Source: British Journal of Ophthalmology)

Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug

Journal of Clinical Pharmacy and Therapeutics — Fri, 05 Feb 2010 00:00:00 +0100

What is known and background: Two receptor signaling pathways that are commonly active in facilitating glioblastoma growth and invasion- that of CCR5 and neurokinin (NK)-1R- have small molecule inhibitors that are FDA approved and marketed to treat other conditions. The anti-HIV drug, maraviroc, inhibits human CCR5's ligand from binding, and hence blocks CCR5 stimulation. The anti-nausea drug aprepitant blocks substance P signaling at NK-1R.Aims and objective: We propose on the basis of molecular insights that a combination of the two drugs is likely to be useful in the treatment of glioblastoma.Comment: After stimulation by their respective ligands both CCR5 and NK-1R, through intermediaries, phosphorylate and thereby activate ERK1/2, triggering in turn migratory and mitotic events. Neuro...

Anti-Vascular Endothelial Growth Factor Therapies and Cardiovascular Toxicity: What Are the Important Clinical Markers to Target?

The Oncologist — Fri, 05 Feb 2010 00:00:00 +0100

Conclusions. In anticipation of cardiovascular complications with anti-VEGF therapies, early detection and personalized management may improve clinical outcomes and tolerance. PMID: 20139170 [PubMed - as supplied by publisher] (Source: The Oncologist)

Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy

Graefe's Archive for Clinical and Experimental Ophthalmology — Thu, 04 Feb 2010 18:10:15 +0100

Conclusions A preoperative intravitreal injection of bevacizumab may represent a new strategy for the surgical treatment of severe PDR by reducing retinal and iris neovascularization: this would make surgery much easier and safer, thus improving the anatomical and functional prognosis. According to our study, the best surgical results are achieved performing the IVB 7 days preoperatively. Content Type Journal ArticleCategory Retinal DisordersDOI 10.1007/s00417-010-1303-3Authors Raffaello di Lauro, Department of Ophthalmology, Hospital C.T.O. of Naples Naples ItalyPio De Ruggiero, Department of Ophthalmology, Hospital C.T.O. of Naples Naples ItalyRaffaella di Lauro, Department of Ophthalmology, Hospital C.T.O. of Naples Naples ItalyMaria Teresa di Lauro, Departmen...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Letrozole plus bevacizumab ‘feasible’ for metastatic breast cancer

MedWire News - Oncology — Thu, 04 Feb 2010 13:48:30 +0100

Treatment with the aromatase inhibitior letrozole plus the anti-vascular endothelial growth factor antibody bevacizumab is feasible in postmenopausal patients with hormone receptor-positive metastatic breast cancer, US research shows. (Source: MedWire News - Oncology)

Letrozole plus bevacizumab ‘feasible’ for metastatic breast cancer

MedWire News - Breast Cancer — Thu, 04 Feb 2010 00:00:00 +0100

Drugs May Be Beneficial in Age-Related Macular Degeneration

Modern Medicine — Thu, 04 Feb 2010 00:00:00 +0100

In patients with exudative age-related macular degeneration, intravitreal bevacizumab or ranibizumab may help stabilize the loss of visual acuity, according to a study in the February issue of Ophthalmology. (Source: Modern Medicine)

Novel EphB4 Monoclonal Antibodies Modulate Angiogenesis and Inhibit Tumor Growth.

The American Journal of Pathology — Thu, 04 Feb 2010 00:00:00 +0100

Authors: Krasnoperov V, Kumar SR, Ley E, Li X, Scehnet J, Liu R, Zozulya S, Gill PS EphB4 receptor tyrosine kinase and its cognate ligand EphrinB2 regulate induction and maturation of newly forming vessels. Inhibition of their interaction arrests angiogenesis, vessel maturation, and pericyte recruitment. In addition, EphB4 is expressed in the vast majority of epithelial cancers and provides a survival advantage to most. Here, we describe two anti-EphB4 monoclonal antibodies that inhibit tumor angiogenesis and tumor growth by two distinct pathways. MAb131 binds to fibronectin-like domain 1 and induces degradation of human EphB4, but not murine EphB4. MAb131 inhibits human endothelial tube formation in vitro and growth of human tumors expressing EphB4 in vivo. In contrast, MAb47 targets ...